Ticker League

Revenue for Biogen (BIIB)

Latest filings through · Reported

Metric

TTM

$9.86B

YoY change

+1.4%

5Y CAGR

-6.1%

Peak year (2019)

$14.38B

Revenue history chart for Biogen (BIIB) from 1985 to 2025

Latest: $9.81B

Revenue growth chart for Biogen (BIIB) from 1985 to 2025

Latest: +1.4%

Revenue history table for Biogen (BIIB) from 1985 to 2025

  • 2025$9.81B+1.4%
  • 2024$9.68B-1.6%
  • 2023$9.84B-3.3%
  • 2022$10.17B-7.4%
  • 2021$10.98B-18.3%
  • 2020$13.44B-6.5%
  • 2019$14.38B+6.9%
  • 2018$13.45B+9.6%
  • 2017$12.27B+7.2%
  • 2016$11.45B+6.4%
  • 2015$10.76B+10.9%
  • 2014$9.70B+40.0%
  • 2013$6.93B+25.7%
  • 2012$5.51B+9.2%
  • 2011$5.05B+7.0%
  • 2010$4.72B+7.7%
  • 2009$4.38B+6.8%
  • 2008$4.10B+29.2%
  • 2007$3.17B+18.2%
  • 2006$2.68B+56.6%
  • 2005$1.71B+7.4%
  • 2004$1.60B+757.3%
  • 2003$186.13M-54.0%
  • 2002$404.22M-61.2%
  • 2001$1.04B+12.6%
  • 2000$925.66M+16.5%
  • 1999$794.43M+42.5%
  • 1998$557.59M+28.5%
  • 1997$434.04M+56.6%
  • 1996$277.09M+82.7%
  • 1995$151.69M-3.0%
  • 1994$156.34M+14.6%
  • 1993$136.40M+10.3%
  • 1992$123.70M+101.5%
  • 1991$61.40M+22.6%
  • 1990$50.10M+75.8%
  • 1989$28.50M+38.3%
  • 1988$20.60M+139.5%
  • 1987$8.60M+34.4%
  • 1986$6.40M-57.6%
  • 1985$15.10M—

Revenue values are taken from Biogen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Revenue at Biogen (BIIB)

According to Biogen's latest reported financial statements, the company's current revenue (TTM) is $9.86B. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

In 2025, Biogen (BIIB) revenue totalled $9.81B – edged up 1.4% year-over-year.

Through 2020–2025 (5 years), Biogen revenue delivered a -6.1% annualised rate; with a net decline across the window.

Between 2019 and 2025, Biogen revenue plunged 31.8%, falling from $14.38B to $9.81B.

The record annual revenue stands at $14.38B, reached in 2019; the historical low of $6.40M was recorded in 1986.

Biogen Revenue by Year

Biogen Revenue 2025: $9.81B

In 2025, Biogen reported revenue of $9.81B, edged up 1.4% from 2024.

Biogen Revenue 2024: $9.68B

Biogen revenue in 2024 was $9.68B, edged down 1.6% below 2023.

Biogen Revenue 2023: $9.84B

2023's revenue for Biogen came in at $9.84B, edged down 3.3% below 2022.

Biogen Revenue 2022: $10.17B

Biogen posted revenue of $10.17B in 2022, declined 7.4% below 2021.

Biogen Revenue 2021: $10.98B

Biogen revenue in 2021 was $10.98B.

See more financial history for Biogen (BIIB).

Sector peers by Revenue

Healthcare peers of Biogen (BIIB), ranked by their latest revenue

Frequently asked questions

Biogen (BIIB) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation